[1] |
DU Caifeng, MAO Yunan, GAO Jia, WANG Juan, LI Xiaoye, TIAN Junsheng, LIU Hongqi.
Research on serum metabolic markers of menopausal syndrome based on 1H-NMR metabolomics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 961-968.
|
[2] |
LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin.
Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
|
[3] |
WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu.
Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
|
[4] |
WANG Jingang, LI Qiang, SUN Huiyan, WANG Hongquan.
Recent progress in understanding the neuroprotective mechanism of carnosic acid in Parkinson's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1073-1080.
|
[5] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[6] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[7] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[8] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[9] |
WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan.
Research progress on diagnosis and treatment of granulomatous lobular mastitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
|
[10] |
WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng.
Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
|
[11] |
FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua.
Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
|
[12] |
WANG Xinyu, CHEN Yipeng, MA Yongli, HE Junfei.
Study of the improvement effect of "DuZhong-DangGui" on osteoarthritis rats via regulating NLPR3 inflammasome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 751-757.
|
[13] |
LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao.
Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
|
[14] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[15] |
YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen.
Research progress in plasma concentration monitoring of rivaroxaban
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 809-817.
|